Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.710
+0.090 (5.56%)
At close: May 12, 2025, 4:00 PM
1.690
-0.020 (-1.17%)
After-hours: May 12, 2025, 6:40 PM EDT
Fractyl Health Revenue
In the year 2024, Fractyl Health had annual revenue of $93.00K, down -22.50%. Fractyl Health had revenue of $3.00K in the quarter ending December 31, 2024, a decrease of -57.14%.
Revenue (ttm)
$93.00K
Revenue Growth
-22.50%
P/S Ratio
900.54
Revenue / Employee
$869
Employees
107
Market Cap
83.75M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GUTS News
- 6 days ago - Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference - GlobeNewsWire
- 14 days ago - Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation - GlobeNewsWire
- 2 months ago - Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 - GlobeNewsWire
- 3 months ago - Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 - GlobeNewsWire
- 5 months ago - Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - GlobeNewsWire